Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels

Sandra Jastrzebski, Judith Kalinowski, Marina Stolina, Faryal Mirza, Elena Torreggiani, Ivo Kalajzic, Hee Yeon Won, Sun Kyeong Lee, Joseph Lorenzo

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

We examined the effects that ovariectomy had on sclerostin mRNA and protein levels in the bones of 8-week-old mice that were either sham-operated (SHAM) or ovariectomized (OVX) and then euthanized 3 or 6 weeks later. In this model, bone loss occurred between 3 and 5 weeks postsurgery. In calvaria, ovariectomy significantly decreased sclerostin mRNA levels at 6 weeks postsurgery (by 52%) but had no significant effect at 3 weeks. In contrast, sclerostin mRNA levels were significantly lower in OVX femurs at 3 weeks postsurgery (by 53%) but equal to that of SHAM at 6 weeks. The effects of ovariectomy on sclerostin were not a global response of osteocytes because they were not mimicked by changes in the mRNA levels for two other relatively osteocyte-specific genes: DMP-1 and FGF-23. Sclerostin protein decreased by 83% and 60%, at 3 and 6 weeks postsurgery in calvaria, respectively, and by 38% in lumbar vertebrae at 6 weeks. We also detected decreases in sclerostin by immunohistochemistry in cortical osteocytes of the humerus at 3 weeks postsurgery. However, there were no significant effects of ovariectomy on sclerostin protein in femurs or on serum sclerostin at 3 and 6 weeks postsurgery. These results demonstrate that ovariectomy has variable effects on sclerostin mRNA and protein in mice, which are dependent on the bones examined and the time after surgery. Given the discrepancy between the effects of ovariectomy on serum sclerostin levels and sclerostin mRNA and protein levels in various bones, these results argue that, at least in mice, serum sclerostin levels may not accurately reflect changes in the local production of sclerostin in bones. Additional studies are needed to evaluate whether this is also the case in humans.

Original languageEnglish
Pages (from-to)618-626
Number of pages9
JournalJournal of Bone and Mineral Research
Volume28
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Ovariectomy
Bone and Bones
Osteocytes
Messenger RNA
Serum
Proteins
Skull
Femur
Fibroblast Growth Factor 1
Lumbar Vertebrae
Humerus
Immunohistochemistry
Genes

Keywords

  • BONE
  • OSTEOCYTE
  • OVARIECTOMY
  • SCLEROSTIN
  • SERUM

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Jastrzebski, S., Kalinowski, J., Stolina, M., Mirza, F., Torreggiani, E., Kalajzic, I., ... Lorenzo, J. (2013). Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. Journal of Bone and Mineral Research, 28(3), 618-626. https://doi.org/10.1002/jbmr.1773

Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. / Jastrzebski, Sandra; Kalinowski, Judith; Stolina, Marina; Mirza, Faryal; Torreggiani, Elena; Kalajzic, Ivo; Won, Hee Yeon; Lee, Sun Kyeong; Lorenzo, Joseph.

In: Journal of Bone and Mineral Research, Vol. 28, No. 3, 03.2013, p. 618-626.

Research output: Contribution to journalArticle

Jastrzebski, S, Kalinowski, J, Stolina, M, Mirza, F, Torreggiani, E, Kalajzic, I, Won, HY, Lee, SK & Lorenzo, J 2013, 'Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels', Journal of Bone and Mineral Research, vol. 28, no. 3, pp. 618-626. https://doi.org/10.1002/jbmr.1773
Jastrzebski, Sandra ; Kalinowski, Judith ; Stolina, Marina ; Mirza, Faryal ; Torreggiani, Elena ; Kalajzic, Ivo ; Won, Hee Yeon ; Lee, Sun Kyeong ; Lorenzo, Joseph. / Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels. In: Journal of Bone and Mineral Research. 2013 ; Vol. 28, No. 3. pp. 618-626.
@article{9f3d27eab68a478686ed01e7df07309b,
title = "Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels",
abstract = "We examined the effects that ovariectomy had on sclerostin mRNA and protein levels in the bones of 8-week-old mice that were either sham-operated (SHAM) or ovariectomized (OVX) and then euthanized 3 or 6 weeks later. In this model, bone loss occurred between 3 and 5 weeks postsurgery. In calvaria, ovariectomy significantly decreased sclerostin mRNA levels at 6 weeks postsurgery (by 52{\%}) but had no significant effect at 3 weeks. In contrast, sclerostin mRNA levels were significantly lower in OVX femurs at 3 weeks postsurgery (by 53{\%}) but equal to that of SHAM at 6 weeks. The effects of ovariectomy on sclerostin were not a global response of osteocytes because they were not mimicked by changes in the mRNA levels for two other relatively osteocyte-specific genes: DMP-1 and FGF-23. Sclerostin protein decreased by 83{\%} and 60{\%}, at 3 and 6 weeks postsurgery in calvaria, respectively, and by 38{\%} in lumbar vertebrae at 6 weeks. We also detected decreases in sclerostin by immunohistochemistry in cortical osteocytes of the humerus at 3 weeks postsurgery. However, there were no significant effects of ovariectomy on sclerostin protein in femurs or on serum sclerostin at 3 and 6 weeks postsurgery. These results demonstrate that ovariectomy has variable effects on sclerostin mRNA and protein in mice, which are dependent on the bones examined and the time after surgery. Given the discrepancy between the effects of ovariectomy on serum sclerostin levels and sclerostin mRNA and protein levels in various bones, these results argue that, at least in mice, serum sclerostin levels may not accurately reflect changes in the local production of sclerostin in bones. Additional studies are needed to evaluate whether this is also the case in humans.",
keywords = "BONE, OSTEOCYTE, OVARIECTOMY, SCLEROSTIN, SERUM",
author = "Sandra Jastrzebski and Judith Kalinowski and Marina Stolina and Faryal Mirza and Elena Torreggiani and Ivo Kalajzic and Won, {Hee Yeon} and Lee, {Sun Kyeong} and Joseph Lorenzo",
year = "2013",
month = "3",
doi = "10.1002/jbmr.1773",
language = "English",
volume = "28",
pages = "618--626",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels

AU - Jastrzebski, Sandra

AU - Kalinowski, Judith

AU - Stolina, Marina

AU - Mirza, Faryal

AU - Torreggiani, Elena

AU - Kalajzic, Ivo

AU - Won, Hee Yeon

AU - Lee, Sun Kyeong

AU - Lorenzo, Joseph

PY - 2013/3

Y1 - 2013/3

N2 - We examined the effects that ovariectomy had on sclerostin mRNA and protein levels in the bones of 8-week-old mice that were either sham-operated (SHAM) or ovariectomized (OVX) and then euthanized 3 or 6 weeks later. In this model, bone loss occurred between 3 and 5 weeks postsurgery. In calvaria, ovariectomy significantly decreased sclerostin mRNA levels at 6 weeks postsurgery (by 52%) but had no significant effect at 3 weeks. In contrast, sclerostin mRNA levels were significantly lower in OVX femurs at 3 weeks postsurgery (by 53%) but equal to that of SHAM at 6 weeks. The effects of ovariectomy on sclerostin were not a global response of osteocytes because they were not mimicked by changes in the mRNA levels for two other relatively osteocyte-specific genes: DMP-1 and FGF-23. Sclerostin protein decreased by 83% and 60%, at 3 and 6 weeks postsurgery in calvaria, respectively, and by 38% in lumbar vertebrae at 6 weeks. We also detected decreases in sclerostin by immunohistochemistry in cortical osteocytes of the humerus at 3 weeks postsurgery. However, there were no significant effects of ovariectomy on sclerostin protein in femurs or on serum sclerostin at 3 and 6 weeks postsurgery. These results demonstrate that ovariectomy has variable effects on sclerostin mRNA and protein in mice, which are dependent on the bones examined and the time after surgery. Given the discrepancy between the effects of ovariectomy on serum sclerostin levels and sclerostin mRNA and protein levels in various bones, these results argue that, at least in mice, serum sclerostin levels may not accurately reflect changes in the local production of sclerostin in bones. Additional studies are needed to evaluate whether this is also the case in humans.

AB - We examined the effects that ovariectomy had on sclerostin mRNA and protein levels in the bones of 8-week-old mice that were either sham-operated (SHAM) or ovariectomized (OVX) and then euthanized 3 or 6 weeks later. In this model, bone loss occurred between 3 and 5 weeks postsurgery. In calvaria, ovariectomy significantly decreased sclerostin mRNA levels at 6 weeks postsurgery (by 52%) but had no significant effect at 3 weeks. In contrast, sclerostin mRNA levels were significantly lower in OVX femurs at 3 weeks postsurgery (by 53%) but equal to that of SHAM at 6 weeks. The effects of ovariectomy on sclerostin were not a global response of osteocytes because they were not mimicked by changes in the mRNA levels for two other relatively osteocyte-specific genes: DMP-1 and FGF-23. Sclerostin protein decreased by 83% and 60%, at 3 and 6 weeks postsurgery in calvaria, respectively, and by 38% in lumbar vertebrae at 6 weeks. We also detected decreases in sclerostin by immunohistochemistry in cortical osteocytes of the humerus at 3 weeks postsurgery. However, there were no significant effects of ovariectomy on sclerostin protein in femurs or on serum sclerostin at 3 and 6 weeks postsurgery. These results demonstrate that ovariectomy has variable effects on sclerostin mRNA and protein in mice, which are dependent on the bones examined and the time after surgery. Given the discrepancy between the effects of ovariectomy on serum sclerostin levels and sclerostin mRNA and protein levels in various bones, these results argue that, at least in mice, serum sclerostin levels may not accurately reflect changes in the local production of sclerostin in bones. Additional studies are needed to evaluate whether this is also the case in humans.

KW - BONE

KW - OSTEOCYTE

KW - OVARIECTOMY

KW - SCLEROSTIN

KW - SERUM

UR - http://www.scopus.com/inward/record.url?scp=84873956617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873956617&partnerID=8YFLogxK

U2 - 10.1002/jbmr.1773

DO - 10.1002/jbmr.1773

M3 - Article

C2 - 23044658

AN - SCOPUS:84873956617

VL - 28

SP - 618

EP - 626

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 3

ER -